EBS News and Press, Emergent Biosolutions Inc. From 08/06/20

Investment Thesis The stakes have never been higher in the battle for a promising COVID-19 vaccine. The valuations of developers have reached a peak leaving no room for error. Several contracts to manufacture the experimental vaccine candidates have turned Emergent BioSolutions, Inc. (EBS)...

Given the massive amounts of uncertainty in the market right now, prudent investors should plan ahead to protect their portfolios against the next crash. Of course, finding an affordable safe harbor at the same time as everyone else is easier said than done, especially when the market is loiteri...

Emergent BioSolutions (NYSE: EBS ) has priced upsized offering of $450M (from $400M) of 3.875% senior unsecured notes due 2028. More news on: Emergent BioSolutions Inc., Healthcare stocks news, , Stocks on the move, Read more ...

GAITHERSBURG, Md., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has priced its offering of $450 million aggregate principal amount of 3.875% Senior Unsecured Notes due 2028 (the “Notes”), represen...

GAITHERSBURG, Md., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it intends to offer $400 million aggregate principal amount of senior unsecured notes with an expected maturity date of August 2028 (the “Note...

Whether your retirement is on the near horizon or still a long way off, it's important to build a diversified portfolio of dividend-paying stocks that you can rely on for healthy yields and ongoing returns. If you're thinking about investing in pharmaceutical stocks to bankroll your retirement...

Shares of Emergent BioSolutions (NYSE: EBS) were up 13.5% at 1:32 p.m. EDT on Friday after the company reported a 62.3% increase in second-quarter revenue, and management said to expect more growth in the second half of the year. Emergent BioSolutions' revenue tends to be lumpy since it's...

Since the coronavirus pandemic first started making waves in January, the number of companies working to develop a treatment has skyrocketed. More than 160 potential COVID-19 vaccines are currently in development, and that figure doesn't even include other types of treatment (such as antivirals)...

Emergent BioSolutions, Inc. (EBS) Q2 2020 Earnings Conference Call July 30, 2020 17:00 ET Company Participants Bob Burrows - Vice President, Investor Relations Bob Kramer - President & Chief Executive Officer Rich Lindahl - Chief Financial Officer Syed Husain - Senior Vice ...

Image source: The Motley Fool. Emergent BioSolutions Inc   (NYSE: EBS) Q2 2020 Earnings Call Jul 30, 2020 , 5:00 p.m. ET Operator Continue reading